17 April 2018 - Deborah Wilkes
Stada Arzneimittel has made several changes to its senior management team, including a new member of the executive board and new heads of business development, emerging markets and Europe.
The German company said the changes would help implement its new "three-pillar strategy" involving OTC products, generics, and specialty pharmaceuticals including biosimilars (click here to read the News story).
The new board member is Miguel Pagan, head of global technical operations at Sandoz and global head of solids and special tech for Sandoz' parent company Novartis. Prior to joining Sandoz, Pagan was vice president of Americas operations for US-based Merck & Co.
Pagan will be the member of Stada's executive board with responsibility for production and development. He replaces Barthold Piening who is leaving Stada at the end of May 2018 to "pursue new career opportunities".
Stada said Pagan was a proven production and operations expert with many years of experience managing international production networks in large pharmaceutical groups.
Promoting Robert Knerr
In addition to recruiting Pagan, Stada is promoting Robert Knerr to executive vice president of global business development. The company said Knerr, who is currently vice president portfolio management, would replace Wolter Kuizinga by 1 September 2018 at the latest.
Knerr’s position in portfolio management will be taken by Stefan Busemann, who is joining Stada from Sandoz.
Stada has also recruited Steffen Wagner as head of Europe with effect from 1 July 2018. He will take charge of all European markets except for Germany, Russia and the UK.
Wagner is a former managing director of Biogen Germany.
Furthermore, Stada has appointed Carsten Cron as head of emerging markets. Cron joins from Pfizer where he was country manager for Morocco, Tunisia and Libya as well as commercial and business operations lead for North Africa and the Middle East.
Stada noted that the head of Europe and head of emerging markets positions had to date been fulfilled by the company's chief executive officer Claudio Albrecht.
Albrecht became chief executive officer of Stada in September 2017 when the company was acquired by private-equity firms Bain Capital and Cinven. The company said at the time that Albrecht would serve as interim head until a permanent chief executive officer was appointed.
New chief executive officer
Stada recently appointed Peter Goldschmidt – a senior executive at Sandoz – as its new permanent chief executive officer. He will take up the post on 1 September 2018.
Reporting its financial results for 2017, Stada said sales were up by 6% to EUR2.26 billion (USD2.86 billion) adjusted for the impact of portfolio and currency changes. As reported, sales grew by 8% to EUR2.31 billion.
The Branded Products business recorded sales up by 11% as reported to EUR952 million.
Read all about the strategies of important OTC players, including Stada, in the OTC Company Strategies 2018 Report published by the OTCToolbox website in March 2018.
– 270 pages
– Executive Summary of key global OTC/consumer healthcare trends
– 18 OTC/consumer healthcare Company Strategy Profiles
Click here to purchase and download.
OTCToolbox Annual Subscription holders can download the report for free by logging into the website.